NOV 09, 2017 12:00 PM PST

Understanding T Cell Responses in Tuberculosis-Latest research on QuantiFERON-TB Gold Plus

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Director: Product and Assay Development North Americas, QIAGEN
    Biography
      Dr. Boyle has over 20 years of experience in immunology research and commercial development relevant to vaccines, biologics and diagnostics. He has published more than 25 papers including Nature, Proc. Natl. Acad. Sci., J. Clin. Microbiol., Vaccine, Int. Immunol. and Transplantation. In addition, he acquired several high-level awards, including top academic achievement each year of undergraduate studies and the Victorian Premiers award for Medical Research. Currently he has an assay development focus on utilizing whole blood assays of cellular immune function for providing insights into unmet medical needs in infectious diseases and transplantation. He is an inventor on several patents relevant to current products and played key roles in leading teams necessary for taking them from concept through to registration.

    Abstract:

    QuantiFERON TB (QFT) was the first interferon gamma release assay (IGRA) utilizing whole blood stimulation as a test for TB infection, gaining FDA approval in 2001. Subsequently there have been several improvements to the first test in terms of accuracy, ease of use and clinical utility.  There are currently over 1200 independent publications on QFT and it is the most studied IGRA in the world on contact evaluation, epidemiology, vaccine and Pharma development and biomarker research. The 4th generation (QFT-Plus) is currently FDA approved in the USA and is CE marked in Europe. QFT-Plus provides higher specificity than the tuberculin skin test (TST) by incorporating highly specific antigens that do not cross react with BCG and most environmental non tuberculosis mycobacteria. In addition, it has new antigens that stimulate CD8 T cells.

    Published studies now supports a role for CD8+ T cells participating in the host defense to MTB by producing IFN-γ and other soluble factors, which activate macrophages to suppress growth of MTB, kill infected cells, or directly lyse intracellular MTB (1-3). MTB-specific CD8+ cells have been detected in subjects with LTBI and with active TB disease where IFN-γ producing CD8+ cells may be frequently found (4-6). Moreover, ESAT-6 and CFP-10 specific CD8+ T lymphocytes are described as being more frequently detected in subjects with active TB disease versus LTBI, and may be associated with a recent MTB exposure (7-9). In addition, MTB-specific CD8+ T cells producing IFN-γ have also been detected in active TB subjects with HIV co-infection (10, 11) and in young children with TB disease (12).  How the incorporation of novel CD8 antigen stimulation technology has proved beneficial in independent performance studies with QFT-Plus in active TB and contact investigations will be discussed.  Maintaining the performance and ease of use of whole blood stimulation builds on the value of QFT and will provide further benefit in the management of latent tuberculosis and TB control programs.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUL 31, 2019 09:00 AM PDT
    C.E. CREDITS
    JUL 31, 2019 09:00 AM PDT
    DATE: July 31, 2019TIME: 9:00am PT, 12:00pm ET The choroid plexus, which makes up the blood-cerebrospinal fluid barrier in the central nervous system (CNS), lines the ventricle...
    DEC 10, 2019 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 10, 2019 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees